Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 13/20 | 0.35 |
| ▸ | HTR7 | P34969 | 13/20 | 0.35 |
| ▸ | DRD2 | P14416 | 10/20 | 0.35 |
| ▸ | HTR6 | P50406 | 10/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23519429 | 0.99 | TP53 (0.37) | TP53ALDH1A1SMN1; SMN2HTR1AHTR7 | |
| SCHEMBL17803853 | 0.91 | TP53 (0.40) | TP53ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL16974355 | 0.89 | TP53 (0.40) | TP53ALDH1A1SMN1; SMN2HTR1AHTR7 | |
| SCHEMBL2380417 | 0.89 | ALDH1A1 (0.42) | TP53ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL30326680 | 0.80 | TP53 (0.35) | TP53ALDH1A1HTR1AHTR7DRD2 | |
| SCHEMBL27089937 | 0.80 | TPSAB1 (0.43) | ALDH1A1HTR1AHTR7DRD2HTR6 | |
| SCHEMBL29742315 | 0.80 | TP53 (0.43) | TP53ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL23031865 | 0.78 | KDM4E (0.36) | TP53SMN1; SMN2 | |
| SCHEMBL15326722 | 0.78 | TP53 (0.42) | TP53ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL30943672 | 0.76 | KDM4E (0.37) | TP53LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12472267-B2 | Compositions containing nucleic acid nanoparticles with modular functionality | Sixfold Bioscience Ltd. (GB) | 2025-11-18 | — | — | US | claimed |
| US-20240384269-A1 | COMPOSITIONS CONTAINING NUCLEIC ACID NANOPARTICLES AND PROCESSES RELATED TO ALTERATION OF THEIR PHYSIOCHEMICAL CHARACTERISTICS | Sixfold Bioscience Ltd. (GB) | 2024-11-21 | — | — | US | claimed |
| US-20240316249-A1 | INJECTION FORMULATION COMPOSITION FOR USE AS FILLER OR DRUG CARRIER THROUGH CLICK CHEMISTRY REACTION | Ajou University Industry-Academic Corporation Foundation (KR) | 2024-09-26 | — | — | US | claimed |
| CN-118546380-A | Biodegradable polymer, preparation method and application thereof, and medical filling material | 上海发微医用材料有限公司 | 2024-08-27 | — | — | CN | claimed |
| EP-4323517-A2 | COMPOSITIONS CONTAINING NUCLEIC ACID NANOPARTICLES AND PROCESSES RELATED TO ALTERATION OF THEIR PHYSICOCHEMICAL CHARACTERISTICS | Sixfold Bioscience Ltd. (GB) | 2024-02-21 | — | — | EP | claimed |
| EP-3581175-B1 | DRUG DRUG DELIVERY FORMULATION FOR TREATING MENTAL ILLNESS OR CENTRAL NERVOUS SYSTEM DISORDER | UNIV AJOU IND ACADEMIC COOP FOUND (KR) | 2023-12-13 | — | — | EP | claimed |
| CN-116392580-A | Type 1 diabetes multi-antigen vaccine preparation and application thereof | 中国科学技术大学 | 2023-07-07 | — | — | CN | claimed |
| CN-115997016-A | Composition comprising nucleic acid nanoparticles having modular functional groups | 西克斯福德生物科学有限公司 | 2023-04-21 | — | — | CN | claimed |
| EP-4143316-A2 | COMPOSITIONS CONTAINING NUCLEIC ACID NANOPARTICLES WITH MODULAR FUNCTIONALITY | Sixfold Bioscience Ltd. (GB) | 2023-03-08 | — | — | EP | claimed |
| US-20220370635-A1 | COMPOSITIONS CONTAINING NUCLEIC ACID NANOPARTICLES WITH MODULAR FUNCTIONALITY | SIXFOLD BIOSCIENCE LTD (GB) | 2022-11-24 | — | — | US | claimed |
| WO-2022219409-A2 | COMPOSITIONS CONTAINING NUCLEIC ACID NANOPARTICLES AND PROCESSES RELATED TO ALTERATION OF THEIR PHYSICOCHEMICAL CHARACTERISTICS | Sixfold Bioscience Ltd. (GB) | 2022-10-20 | — | — | WO | claimed |
| US-11357865-B2 | Compositions containing nucleic acid nanoparticles with modular functionality | Sixfold Bioscience Ltd. (GB) | 2022-06-14 | — | — | US | claimed |
| US-11337929-B2 | Drug delivery formulation for treating mental illness or central nervous system disorder | AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2022-05-24 | — | — | US | claimed |
| EP-4737574-A2 | POLY-TAILED AND POLY-CAPPED MRNA AND USES THEREOF | The Broad Institute Inc. (US) | 2026-05-06 | — | — | EP | disclosed |
| US-12551572-B2 | Modified viral particles for gene therapy | EUROPEAN MOLECULAR BIOLOGY LABORATORY (DE) | 2026-02-17 | — | — | US | disclosed |
| US-12544455-B2 | Targeted poly(beta-amino ester)s | IXAKA FRANCE (FR) | 2026-02-10 | — | — | US | disclosed |
| US-11357865-B2 | Compositions containing nucleic acid nanoparticles with modular functionality | Sixfold Bioscience Ltd. (GB) | 2022-06-14 | — | — | US | disclosed |
| CN-114630907-A | anti-CD 3 aptamers for cell targeting and labeling | 艾夏卡法国有限公司 | 2022-06-14 | — | — | CN | disclosed |
| US-11337929-B2 | Drug delivery formulation for treating mental illness or central nervous system disorder | AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2022-05-24 | — | — | US | disclosed |
| WO-2022101363-A1 | MODIFIED VIRAL PARTICLES FOR GENE THERAPY | EUROPEAN MOLECULAR BIOLOGY LABORATORY (DE) | 2022-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11357865-B2 | Compositions containing nucleic acid nanoparticles with modular functionality | NCL, NSUN3, POLN | TP53 218/4885ALDH1A1 2270/4885SMN1; SMN2 657/4885 |
| US-12551572-B2 | Modified viral particles for gene therapy | SMCHD1, SMC1A, TIMCC | TP53 1424/4885ALDH1A1 1670/4885SMN1; SMN2 95/4885 |
| US-12544455-B2 | Targeted poly(beta-amino ester)s | DNER, POTEE, BCAT1 | TP53 1867/4885ALDH1A1 840/4885SMN1; SMN2 1128/4885 |
| US-20220370635-A1 | COMPOSITIONS CONTAINING NUCLEIC ACID NANOPARTICLES WITH MODULAR FUNCTIONALITY | NCL, NSUN3, POLN | TP53 218/4885ALDH1A1 2270/4885SMN1; SMN2 657/4885 |
| US-12472267-B2 | Compositions containing nucleic acid nanoparticles with modular functionality | NCL, NSUN3, POLN | TP53 218/4885ALDH1A1 2270/4885SMN1; SMN2 657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.